Clinical trial
Treatment With SU11248 in Patients With Neuroendocrine Tumors
NCT00056693 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00056693 |
|---|---|
| Title | Treatment With SU11248 in Patients With Neuroendocrine Tumors |
| Official title | A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Advanced Unresectable Neuroendocrine Tumor |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroendocrine Tumors |
| Intervention type | Drug |
| Interventions | Sunitinib |
| Enrollment | 107 |
| Start date | Apr 1, 2003 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Mar 24, 2003 |
| Last update posted | Jul 21, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: